The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.
 
Mitsuhiko Iwamoto
No Relationships to Disclose
 
Kosei Kimura
No Relationships to Disclose
 
Satoru Tanaka
No Relationships to Disclose
 
Daigo Yamamoto
No Relationships to Disclose
 
Katsuhide Yoshidome
No Relationships to Disclose
 
Hiroyuki Ogura
No Relationships to Disclose
 
Risa Terasawa
No Relationships to Disclose
 
Nobuki Matsunami
No Relationships to Disclose
 
Yuko Takahashi
No Relationships to Disclose
 
Toshikatsu Nitta
No Relationships to Disclose
 
Takashi Morimoto
No Relationships to Disclose
 
Hiroya Fujioka
No Relationships to Disclose
 
Kanako Kawaguchi
No Relationships to Disclose
 
Kazuhisa Uchiyama
No Relationships to Disclose